Pubblicazioni

Per ricevere informazioni su corsi, congressi, novità tecnologiche, aspetti legali e iniziative nel campo delle neuroscienze, iscriviti alla nostra newsletter e seguici sui nostri canali social.

 

Repetitive Transcranial Magnetic Stimulation in Managing Mild Traumatic Brain Injury-Related Headaches

A, Leung; S, Shukla; A, Fallah; D, Song; L, Lin; S, Golshan; A, Tsai; A, Jak; G, Polston; R, Lee
Abstract:
OBJECTIVE: Headache is one of the most common debilitating chronic pain conditions in either active or retired military personnel with mild traumatic brain injury (MTBI). This study assessed the effect of repetitive transcranial magnetic stimulation (rTMS) in alleviating MTBI-related headache (MTBI-HA). MATERIALS AND METHOD: Veterans with MTBI-HA were randomized to receive either real rTMS (REAL group) at 10 hz for a total of 2000 pulses divided into 20 trains with one-sec inter-train interval or sham rTMS (SHAM group) at the left motor cortex (LMC) with brain magnetic resonance imaging neuronavigation guidance. Pretreatment, posttreatment one-week and four-week headache and neuropsychological assessments were conducted. RESULT: Thirty veterans were screened and twenty four (21 men and 3 women with average year-old ± SD at 14.3 ± 12.6) subjects' data were analyzed. A two-factor (visit × treatment) repeated measures analysis of variance (RM-ANOVA) indicated a close to significant (p = 0.06) trend of interaction between pretreatment and posttreatment one-week assessment with the intensity of the persistent daily headache decreasing from 5.7 ± 1.9 to 2.2 ± 2.7 and 4.6 ± 1.3 to 3.5 ± 2.0 for the REAL and SHAM groups, respectively. Subsequent analyses indicated REAL group demonstrated a significantly (p = 0.041) higher % of reduction in persistent headache intensity than the SHAM group (56.3 ± 48.2% vs.15.4 ± 43.6%) at the posttreatment one-week assessment and the trend continued to the four-week assessment. Overall, a significantly (p = 0.035) higher percentage of the subjects in the REAL group (58.3%) demonstrated at least a 50% headache intensity reduction at posttreatment one-week assessment compared with the SHAM group (16.6%). The overall composite score of functionally debilitating headache exacerbation is significantly (p = 0.017) reduced in REAL group at the posttreatment four-week assessment in comparison with the SHAM group. No major sustained change in neuropsychological assessments was noted. CONCLUSION: The studied rTMS protocol appears to be a clinically feasible and effective treatment option in managing MTBI-HA.
Patologie/Applicazioni:
Anno:
2016
Tipo di pubblicazione:
Articolo
Parola chiave:
riabilitazione cognitiva; neuromodulazione
Testata scientifica:
Neuromodulation
DOI:
10.1111/ner.12364

La nostra storia

GEA soluzioni si affaccia nel 2013 al mercato della strumentazione medicale di alto livello tecnologico ma la sua storia parte da più lontano, clicca qui per approfondire.  

GEA SOLUZIONI SRL
via Issiglio 95/10, Torino
Tel.: 011 5821948
Fax: 011 0433281
Email: info @ geasoluzioni.it

P. IVA IT11696920013
REA TO1233648

Tutti i prodotti esposti sul sito geasoluzioni.it con relativi sottodomini ed aventi la natura di dispositivi medici, dispositivi medico diagnostici, presidi medico chirurgici, medicazioni per uso esterno, nonché tutti i contenuti del sito www.geasoluzioni.it (testi, immagini, foto, disegni, allegati, descrizioni e quant’altro) non hanno carattere né natura di pubblicità. Tutti i contenuti devono intendersi e sono di natura esclusivamente informativa e volti esclusivamente a portare a conoscenza dei clienti o dei potenziali clienti in fase di pre-acquisto i prodotti venduti da GEA soluzioni s.r.l. attraverso la rete. Nessun contenuto delle pagine del sito deve essere inteso come materiale pubblicitario, teso ad influenzare in qualsivoglia maniera una decisione di acquisto.

EU-Cookies

Copyright © 2024 GEA SOLUZIONI SRL. Tutti i diritti riservati.

Search